Movatterモバイル変換


[0]ホーム

URL:


CN103450172A - Preparation method of antipsychotic drug lurasidone - Google Patents

Preparation method of antipsychotic drug lurasidone
Download PDF

Info

Publication number
CN103450172A
CN103450172ACN2012101754064ACN201210175406ACN103450172ACN 103450172 ACN103450172 ACN 103450172ACN 2012101754064 ACN2012101754064 ACN 2012101754064ACN 201210175406 ACN201210175406 ACN 201210175406ACN 103450172 ACN103450172 ACN 103450172A
Authority
CN
China
Prior art keywords
formula
compound
described method
reaction
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012101754064A
Other languages
Chinese (zh)
Inventor
陆荣政
李宏
曾祥萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Trustever Pharmaceutical Co., Ltd.
Original Assignee
GUANGZHOU YAOYUAN BIOLOGICAL MEDICINE SCIENCE & TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGZHOU YAOYUAN BIOLOGICAL MEDICINE SCIENCE & TECHNOLOGY Co LtdfiledCriticalGUANGZHOU YAOYUAN BIOLOGICAL MEDICINE SCIENCE & TECHNOLOGY Co Ltd
Priority to CN2012101754064ApriorityCriticalpatent/CN103450172A/en
Publication of CN103450172ApublicationCriticalpatent/CN103450172A/en
Pendinglegal-statusCriticalCurrent

Links

Landscapes

Abstract

The invention relates to preparation methods of (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazole-3-yl)piperazinyl-1-methyl]cyclohexyl methyl}hexahydro-1H-4,7-methano-isoindole-1,3-dione (a compound represented by a formula I) and intermediates thereof. A hydrochloride (lurasidone hydrochloride) of the compound represented by the formula (I) can be used as a drug for treatment of psychosis.

Description

A kind of preparation method of antipsychotics Lurasidone
Technical field
The present invention relates to a kind of (3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1, the preparation method of 3-diketone (formula I compound) and intermediate thereof.
Background technology
Lurasidone HCl (Lurasidone hydrochloride, commodity are called Latuda) be that it is to serotonin 2A(5-HT2A by the antipsychotic agent with dual function of SUMITOMO CHEMICAL drugmaker exploitation) and d2 dopamine receptor all there is high affinity.The insane positive and recessive symptom are all had to obvious curative effects.Reported the synthetic route of formula (I) in JP 2006169155, with (1R, 2R)-1, 2-cyclohexanedimethanol two methanesulfonates formula (III) compounds are starting raw material, in toluene, reflux obtains methylsulfonic acid quaternary ammonium salt formula V, the quaternary ammonium salt obtained and (3aR, 4S, 7R, 7aS)-4, 7-methylene radical-1H-isoindole-1, 3-2H-bis-keto-acids (VI) reaction, make alkali in reflux in toluene with salt of wormwood, obtain target product (3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1, 2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4, 7-methyl isoindole-1, 3-diketone (formula I compound).But this method solvent for use toxicity is larger, unfriendly to environment, while easy generating portion by product when synthetic target product is done alkali in reflux in toluene with salt of wormwood, the existence of by product makes the purifying of target product be not easy operation, after making with extra care accordingly, to productive rate, can have a great impact, at US 2011263848A1, US2011263847A1 has carried out corresponding optimization to the problem existed, but still have by product to exist, and experimental implementation is more loaded down with trivial details, is difficult for carrying out suitability for industrialized production.
Figure BDA00001702935700011
Summary of the invention
The problem existed for above prior art, the invention provides a kind of (3aR for preparing, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1, the method for 3-diketone (formula I compound).The method is than the prior art easy handling, the experiment condition gentleness, and reaction product is easy to purifying, and productive rate is high, and product purity is good, is easy to realize the characteristics such as suitability for industrialized production.
Figure BDA00001702935700012
The method comprises the following steps
By (1R, 2R)-1,2-CHDM formula (II) and methylsulfonyl chloride reaction, in methylene dichloride ,-20 ° of C ~ 20 ° C, react 5 ~ 24h, obtains formula (III) compound.
Formula (III) compound obtains methylsulfonic acid quaternary ammonium salt formula V compound with 3-(1-piperazinyl)-1,2 benzisothia triazole hydrochloride (formula IV compound) under heating condition.
Figure BDA00001702935700022
By methylsulfonic acid quaternary ammonium salt formula V compound and (3aR, 4S, 7R, 7aS)-4,7-methylene radical-1H-isoindole-1,3-2H-bis-keto-acids (VI) reaction, obtain formula (I) compound.
Figure BDA00001702935700023
As seen from the above technical solution, principal feature of the present invention is:
1. synthetic marketable material (1R, the 2R)-1,2-CHDM of choosing of formula (III) compound is starting raw material, and raw material is easy to get, and the reaction conditions gentleness of synthesis type (III) compound is easy to control, and productive rate is high, is easy to purifying.
2. methylsulfonic acid quaternary ammonium salt formula V compound is synthetic, and selecting acetonitrile is solvent, and reaction conditions is than the toluene gentleness, simple to operate.Obtain product purity high.
3. the synthetic employing DMF of formula (I) is excellent, and the purity of resulting product is high, productive rate is high, the needs of applicable suitability for industrialized production simple to operate, and selected solvent is environmentally friendly, on experiment operator, impact does not almost have, and toluene has great toxicity.
Embodiment
Following examples are to describe in detail the present invention, and unrestricted the present invention.
1. (1R, 2R)-1,2-CHDM two methanesulfonates formulas (III)
Add 500.0g (1R, 2R)-1,2-CHDM in the 10L there-necked flask, the 7500ml methylene dichloride adds triethylamine 1052.5g successively, methylsulfonyl chloride 835.0g, and after adding, reaction 8h.Add 3750ml purified water agitator treating in reaction system, separatory discards water layer, and organic phase is washed with dilute hydrochloric acid, then successively with saturated sodium bicarbonate washing, saturated common salt water washing, separatory, organic phase anhydrous sodium sulfate drying.The filtering anhydrous sodium sulphate, be evaporated to dry.Add wherein ether, suction filtration, 60 ℃ of lower forced air dryings of filter cake obtain off-white color solid 889.4g, yield: approximately 85.4%.
2. (3aR, 7aR)-4'-(1,2-benzisothiazole-3-yl) octahydro spiral shell [2H-isoindole-2,1'-piperazine] mesylate formula V
Figure BDA00001702935700031
Add 885.0g (1R in the 20L reaction flask, 2R)-1,2-cyclohexanedimethanol two methanesulfonates formulas (III), 717.7g 3-(1-piperazinyl)-1,2 benzisothia triazole hydrochlorides (formula IV), 775.6g salt of wormwood, the 13.3L acetonitrile is heated with stirring to reflux and starts to reflux, stirring reaction.After reacting completely, filtered while hot, filter cake acetonitrile drip washing, filtrate decompression is concentrated into dry, obtains off-white color solid 1045.9g, yield approximately 88%.HPLC purity is greater than 99%.
3.(3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1,3-diketone (formula I compound)
The 10L there-necked flask adds 625.0g (3aR, 7aR)-4'-(1,2-benzisothiazole-3-yl) octahydro spiral shell [2H-isoindole-2, the 1'-piperazine] mesylate, 248.6g (3aR, 4S, 7R, 7aS)-4,7-methylene radical-1H-isoindole-1,3-2H-bis-keto-acids (VI), 611.8g salt of wormwood, 6250ml DMF, stirring heating heats up, 100 ° of C ~ 130 ° C of temperature control, reaction 36h.Stopped reaction, filtered while hot, filter cake DMF drip washing, filtrate is chilled to room temperature, drips wherein while stirring the 9375ml purified water, continues to stir 2h.Filter, filter cake is dry to the greatest extent with being evacuated to after purified water drip washing, and 55 ℃ of lower vacuum-dryings, obtain the 646g target product, yield 89%, and HPLC is greater than 95%.

Claims (9)

1. one kind prepares (3aR, 4S, 7R, 7aS)-2-{ (1R, 2R)-2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-methyl] cyclohexyl methyl } six hydrogen-1H-4,7-methyl isoindole-1, the method for 3-diketone (formula I compound)
Figure FDA00001702935600011
The method comprises the following steps
By the reaction of (1R, 2R)-1,2-CHDM formula (II) and methylsulfonyl chloride, in methylene dichloride-20 ℃ ~ 20 ℃, react 5 ~ 24h, obtain formula (III) compound
Figure FDA00001702935600012
Formula (III) compound obtains methylsulfonic acid quaternary ammonium salt formula V compound with 3-(1-piperazinyl)-1,2 benzisothia triazole hydrochloride (formula IV compound) under heating condition
By methylsulfonic acid quaternary ammonium salt formula V compound and (3aR, 4S, 7R, 7aS)-4,7-methylene radical-1H-isoindole-1,3-2H-bis-keto-acids (VI) reaction, obtain formula (I) compound
2. according to the described method of right 1, it is characterized in that at synthesis type (III) solvent for use be methylene dichloride, alkali used is triethylamine or DIPEA.
3. according to the described method of right 2, the consumption of triethylamine or DIPEA be 2.2 ~ 5 equivalents with respect to compound formula (I), preferably 2.5 ~ 4.
4. according to the described method of right 2, the consumption of methylsulfonyl chloride be 1.9 ~ 3 equivalents with respect to compound formula (I), preferably 1.9 ~ 2.5.
5. according to the described method of right 1, it is characterized in that synthesis type (III) temperature of reaction-20 ℃ ~ 20 ℃, preferably-10 ℃ ~ 5 ℃, reaction times 5 ~ 24h, preferably 12 ~ 16h.
6. according to the described method of right 1, it is characterized in that at synthetic formula V solvent for use be acetonitrile, dimethylbenzene, DMF, the mixed solvent of N,N-dimethylacetamide or above solvent.
7. according to the described method of right 1, it is characterized in that at synthetic formula V alkali used be salt of wormwood, sodium carbonate, magnesiumcarbonate, 60 ℃ ~ 150 ℃ of temperature of reaction, preferably 80 ℃ ~ 120 ℃, reaction times 24h ~ 120h, preferably 60h ~ 96h.
8. according to the described method of right 1, it is characterized in that at synthesis type (I) solvent for use be DMF, N,N-dimethylacetamide, dioxane, the trimethyl carbinol, propyl carbinol, the mixed solvent of Virahol or above solvent.
9. according to the described method of right 1, it is characterized in that at synthesis type (I) alkali used be salt of wormwood, sodium carbonate, magnesiumcarbonate, calcium hydroxide, 60 ℃ ~ 150 ℃ of temperature of reaction, preferably 100 ℃ ~ 140 ℃.
CN2012101754064A2012-05-302012-05-30Preparation method of antipsychotic drug lurasidonePendingCN103450172A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN2012101754064ACN103450172A (en)2012-05-302012-05-30Preparation method of antipsychotic drug lurasidone

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN2012101754064ACN103450172A (en)2012-05-302012-05-30Preparation method of antipsychotic drug lurasidone

Publications (1)

Publication NumberPublication Date
CN103450172Atrue CN103450172A (en)2013-12-18

Family

ID=49733058

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN2012101754064APendingCN103450172A (en)2012-05-302012-05-30Preparation method of antipsychotic drug lurasidone

Country Status (1)

CountryLink
CN (1)CN103450172A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN109553614A (en)*2017-09-272019-04-02北京万全德众医药生物技术有限公司The preparation of Lurasidone isomer impurities
CN110734434A (en)*2019-11-192020-01-31湖南洞庭药业股份有限公司Method for preparing lurasidone and salt thereof
CN112305096A (en)*2020-09-302021-02-02辰欣药业股份有限公司Detection method of related substances of lurasidone hydrochloride tablets

Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5532372A (en)*1990-07-061996-07-02Sumitomo Pharmaceuticals Company, Ltd.Imide derivatives, and their production and use
US20110263848A1 (en)*2010-04-262011-10-27Dainippon Sumitomo Pharma Co., Ltd.Process of a quaternary ammonium salt using phosphate
US20110263847A1 (en)*2010-04-262011-10-27Dainippon Sumitomo Pharma Co, Ltd.Process of a quaternary ammonium salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5532372A (en)*1990-07-061996-07-02Sumitomo Pharmaceuticals Company, Ltd.Imide derivatives, and their production and use
US20110263848A1 (en)*2010-04-262011-10-27Dainippon Sumitomo Pharma Co., Ltd.Process of a quaternary ammonium salt using phosphate
US20110263847A1 (en)*2010-04-262011-10-27Dainippon Sumitomo Pharma Co, Ltd.Process of a quaternary ammonium salt

Cited By (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN109553614A (en)*2017-09-272019-04-02北京万全德众医药生物技术有限公司The preparation of Lurasidone isomer impurities
CN110734434A (en)*2019-11-192020-01-31湖南洞庭药业股份有限公司Method for preparing lurasidone and salt thereof
CN110734434B (en)*2019-11-192022-11-11湖南洞庭药业股份有限公司Method for preparing lurasidone and salt thereof
CN112305096A (en)*2020-09-302021-02-02辰欣药业股份有限公司Detection method of related substances of lurasidone hydrochloride tablets

Similar Documents

PublicationPublication DateTitle
CN104844585A (en)Preparation method of brexpiprazole
CN110498770B (en) A kind of method for preparing elagolime intermediate
CN101735201B (en)Preparation method of piribedil
CN104829602A (en)Brexpiprazole preparation method
CN104447589A (en)Preparation method and intermediate of uric acid regulator
WO2011160594A1 (en)New preparation method of lapatinib
CN105566215B (en)A kind of Rui Gefeini preparation method
CN104628679A (en)New synthesis method and intermediate of Bitopertin
CN104059025A (en)Novel intermediate used for preparation of avanafil and preparation method thereof
CN103450172A (en)Preparation method of antipsychotic drug lurasidone
CN107235959A (en)A kind of novel method for synthesizing for preparing cancer therapy drug Niraparib
CN105566260A (en)Furosemide preparation method
CN103724336B (en)A kind of synthetic method of novel anticoagulation medicine
CN103880762B (en)A kind of preparation method of 1,2,3-triazole compound
CN105481856A (en)Preparation method of palipefidone
CN107814804A (en)The preparation method of Buddhist nun is replaced according to Shandong
CN103588765A (en)Synthesis method for azilsartan medoxomil or salt thereof, intermediate of azilsartan medoxomil or salt thereof and synthesis method for intermediate
CN107722007B (en)Preparation method of apixaban impurity
CN102060798A (en)Method for synthesizing 2-(1-hydro-4-tetrazole)-4'-methylbiphenyl and derivatives thereof
CN102001973A (en)Method for preparing and refining 1,3-propanedisulfonate
CN104844588A (en)Synthetic method for rivaroxaban related substance diamine
CN107266442A (en)The preparation method of piperidines with antitumor activity and pyridine compounds and their
CN103058950A (en)Preparation method of febuxostat
CN104974059B (en) A kind of rivaroxaban intermediate and preparation method thereof
CN105968108B (en)A kind of method for synthesizing Pabuk former times profit cloth intermediate

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
ASSSuccession or assignment of patent right

Owner name:GUANGDONG TRUSTEVER PHARMACEUTICAL CO., LTD.

Free format text:FORMER OWNER: GUANGZHOU YAOYUAN BIOLOG MEDICINE SCIENCE + TECHNOLOGY CO., LTD.

Effective date:20140307

CORChange of bibliographic data

Free format text:CORRECT: ADDRESS; FROM: 510300 GUANGZHOU, GUANGDONG PROVINCE TO: 510627 GUANGZHOU, GUANGDONG PROVINCE

TA01Transfer of patent application right
TA01Transfer of patent application right

Effective date of registration:20140307

Address after:801 A tower, R & F Intime Plaza, 100 West Whampoa Road, Tianhe District, Guangzhou, Guangdong 510627, China

Applicant after:Guangdong Trustever Pharmaceutical Co., Ltd.

Address before:510300, Guangzhou International Biological Island, No. three, No. 401, A fourth, Guangdong

Applicant before:Guangzhou Yaoyuan Biological Medicine Science & Technology Co., Ltd.

C02Deemed withdrawal of patent application after publication (patent law 2001)
WD01Invention patent application deemed withdrawn after publication

Application publication date:20131218


[8]ページ先頭

©2009-2025 Movatter.jp